Revised porcine IgG subclass classification based on innate immune cell activation. [PDF]
Front ImmunolVan der Weken H +4 more
europepmc +1 more source
Case Report: A case of anti-mGluR1 antibody-associated encephalitis treated with efgartigimod combined with rituximab. [PDF]
Front ImmunolLiu J, Zhu W, Gao L, Zhao C.
europepmc +1 more source
Myasthenia gravis with dysphagia as the first symptom and misdiagnosed as anxiety-depressive state: a case report. [PDF]
Front ImmunolAili K, Maimaiti M.
europepmc +1 more source
Commentary on "Broadly Protective Antibody-Like Vaccines Against Highly Pathogenic Coronaviruses". [PDF]
J Med VirolMumtaz S.
europepmc +1 more source
Anti-IgLON5 disease presenting with myokymia and favourable response to FcRN-antagonist combined with oral glucocorticoids: case report. [PDF]
Front ImmunolShang T +5 more
europepmc +1 more source
Case Report: Anti-LGI1 encephalitis during FcRn inhibition with efgartigimod for myasthenia gravis: implications for the limitations of IgG recycling blockade. [PDF]
Front ImmunolKomatsu Y +5 more
europepmc +1 more source
QSP model for AAV-mediated antibody delivery in rat brain. [PDF]
J Pharmacokinet PharmacodynLiu S +4 more
europepmc +1 more source
Fc-engineering for improved cancer immunotherapy. [PDF]
Biochem Soc TransBorgman E +3 more
europepmc +1 more source
Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions With the Antibody-Drug Conjugate Trastuzumab Deruxtecan. [PDF]
CPT Pharmacometrics Syst PharmacolWatanabe A +6 more
europepmc +1 more source
Physiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients with Inflammatory Bowel Disease. [PDF]
Clin PharmacokinetParikh S +5 more
europepmc +1 more source